A prospective head-to-head comparison of -[68Ga]Ga-P16-093 and -[68Ga]Ga-PSMA-11 PET/CT in patients with primary prostate cancer

被引：12
作者：
Wang, Guochang [1 ]
Li, Linlin [1 ]
Zhu, Ming [2 ]
Zang, Jie [3 ]
Wang, Jiarou [1 ]
Wang, Rongxi [1 ]
Yan, Weigang [2 ]
Zhu, Lin [4 ]
Kung, Hank F. [5 ]
Zhu, Zhaohui [1 ]
机构：
[1] Chinese Acad Med Sci, Peking Union Med Coll, Peking Union Med Coll Hosp, Dept Nucl Med,State Key Lab Complex Severe & Rare, Beijing 100730, Peoples R China
[2] Chinese Acad Med Sci, Peking Union Med Coll, Peking Union Med Coll Hosp, Dept Urol, Beijing 100730, Peoples R China
[3] Fujian Med Univ, Affiliated Hosp 1, Dept Nucl Med, Fuzhou 350005, Peoples R China
[4] Beijing Normal Univ, Minist Educ, Coll Chem, Key Lab Radiopharmaceut, Beijing 100875, Peoples R China
[5] Univ Penn, Dept Radiol, Philadelphia, PA 19104 USA
来源：
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING | 2023年 / 50卷 / 10期
基金：
中国国家自然科学基金; 北京市自然科学基金;
关键词：
Ga-68]Ga-P16-093; Ga-68]Ga-PSMA-11; Prostate cancer; PET/CT; MEMBRANE ANTIGEN PSMA; GA-68-PSMA-11; PET/CT; EXPRESSION;
D O I：
10.1007/s00259-023-06283-4
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
Purpose We aimed to compare the diagnostic performance and biodistribution of two similar PET agents, -[Ga-68]Ga-P16-093 and -[Ga-68]Ga-PSMA-11, in the same group of primary prostate cancer (PCa) patients. Methods Fifty patients with untreated, histologically confirmed PCa by needle biopsy were enrolled. Each patient underwent -[Ga-68]Ga-P16-093 and -[Ga-68]Ga-PSMA-11 PET/CT within a week. In addition to visual analysis, the standardized uptake value ( SUV) was measured for semiquantitative comparison and correlation analysis. Results [Ga-68]Ga-P16-093 PET/CT detected more positive tumors than -[Ga-68]Ga-PSMA-11 PET/CT (202 vs. 190, P = 0.002), both for intraprostatic lesions (48 vs. 41, P = 0.016) and metastatic lesions (154 vs. 149, P = 0.125), especially for intraprostatic lesions in low- and intermediate-risk PCa patients (21/23 vs. 15/23, P = 0.031). Furthermore, -[Ga-68]Ga-P16-093 PET/CT exhibited a significantly higher SUVmax for most matched tumors (13.7 +/- 10.2 vs. 11.4 +/- 8.3, P < 0.001). For normal organs, -[Ga-68]Ga-P16-093 PET/CT showed significantly lower activity in the kidney (SUVmean: 20.1 +/- 6.1 vs. 29.3 +/- 9.1, P < 0.001) and urinary bladder (SUVmean: 6.5 +/- 7.1 vs. 20.9 +/- 17.4, P < 0.001), but displayed a higher uptake in the parotid gland (SUVmean: 8.7 +/- 2.6 vs. 7.6 +/- 2.1, P < 0.001), liver ( SUVmean: 7.0 +/- 1.9 vs. 3.7 +/- 1.3, P < 0.001), and spleen (SUVmean: 8.2 +/- 3.0 vs. 5.2 +/- 2.2, P < 0.001) than -[Ga-68]Ga-PSMA-11 PET/CT. Conclusion [Ga-68] Ga-P16-093 PET/CT demonstrated higher tumor uptake and better tumor detectability than -[Ga-68]GaPSMA-11 PET/CT, especially in low- and intermediate-risk PCa patients, which indicated that -[Ga-68]Ga-P16-093 may serve as an alternative agent for detection of PCa. Trial registration Ga-68-P16-093 and Ga-68-PSMA-11 PET/CT Imaging in the Same Group of Primary Prostate Cancer Patients (NCT05324332, Registered 12 April 2022, retrospectively registered).
引用
收藏
页码：3126 / 3136
页数：11
相关论文
共 31 条
[1]   Assessing extra-prostatic extension for surgical guidance in prostate cancer: Comparing two PSMA-PET tracers with the standard-of-care [J].
Bahler, Clinton D. ;
Green, Mark A. ;
Tann, Mark A. ;
Swensson, Jordan K. ;
Collins, Katrina ;
Alexoff, David ;
Kung, Hank ;
Brocken, Eric ;
Mathias, Carla J. ;
Cheng, Liang ;
Hutchins, Gary D. ;
Koch, Michael O. .
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2023, 41 (01) :48.e1-48.e9
[2]   68Ga-PSMA PET/CT in patients with recurrent prostate cancer after radical treatment: prospective results in 314 patients [J].
Caroli, Paola ;
Sandler, Israel ;
Matteucci, Federica ;
De Giorgi, Ugo ;
Uccelli, Licia ;
Celli, Monica ;
Foca, Flavia ;
Barone, Domenico ;
Romeo, Antonino ;
Sarnelli, Anna ;
Paganelli, Giovanni .
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2018, 45 (12) :2035-2044
[3]  
Chang SS, 1999, CANCER RES, V59, P3192
[4]   68Ga-PSMA I&T PET/CT for primary staging of prostate cancer [J].
Cytawa, Wojciech ;
Seitz, Anna Katharina ;
Kircher, Stefan ;
Fukushima, Kazuhito ;
Tran-Gia, Johannes ;
Schirbel, Andreas ;
Bandurski, Tomasz ;
Lass, Piotr ;
Krebs, Markus ;
Polom, Wojciech ;
Matuszewski, Marcin ;
Wester, Hans-Juergen ;
Buck, Andreas K. ;
Kuebler, Hubert ;
Lapa, Constantin .
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2020, 47 (01) :168-177
[5]   Assessment of 68Ga-PSMA-11 PET Accuracy in Localizing Recurrent Prostate Cancer: A Prospective Single-Arm Clinical Trial [J].
Fendler, Wolfgang P. ;
Calais, Jeremie ;
Eiber, Matthias ;
Flavell, Robert R. ;
Mishoe, Ashley ;
Feng, Felix Y. ;
Nguyen, Hao G. ;
Reiter, Robert E. ;
Rettig, Matthew B. ;
Okamoto, Shozo ;
Emmett, Louise ;
Zacho, Helle D. ;
Ilhan, Harun ;
Wetter, Axel ;
Rischpler, Christoph ;
Schoder, Heiko ;
Burger, Irene A. ;
Gartmann, Jeannine ;
Smith, Raven ;
Small, Eric J. ;
Slavik, Roger ;
Carroll, Peter R. ;
Herrmann, Ken ;
Czernin, Johannes ;
Hope, Thomas A. .
JAMA ONCOLOGY, 2019, 5 (06) :856-863
[6]   68Ga-PSMA PET/CT: Joint EANM and SNMMI procedure guideline for prostate cancer imaging: version 1.0 [J].
Fendler, Wolfgang P. ;
Eiber, Matthias ;
Beheshti, Mohsen ;
Bomanji, Jamshed ;
Ceci, Francesco ;
Cho, Steven ;
Giesel, Frederik ;
Haberkorn, Uwe ;
Hope, Thomas A. ;
Kopka, Klaus ;
Krause, Bernd J. ;
Mottaghy, Felix M. ;
Schoder, Heiko ;
Sunderland, John ;
Wan, Simon ;
Wester, Hans-Juergen ;
Fanti, Stefano ;
Herrmann, Ken .
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2017, 44 (06) :1014-1024
[7]   Local recurrence of prostate cancer after radical prostatectomy is at risk to be missed in 68Ga-PSMA-11-PET of PET/CT and PET/MRI: comparison with mpMRI integrated in simultaneous PET/MRI [J].
Freitag, Martin T. ;
Radtke, Jan P. ;
Afshar-Oromieh, Ali ;
Roethke, Matthias C. ;
Hadaschik, Boris A. ;
Gleave, Martin ;
Bonekamp, David ;
Kopka, Klaus ;
Eder, Matthias ;
Heusser, Thorsten ;
Kachelriess, Marc ;
Wieczorek, Kathrin ;
Sachpekidis, Christos ;
Flechsig, Paul ;
Giesel, Frederik ;
Hohenfellner, Markus ;
Haberkorn, Uwe ;
Schlemmer, Heinz-Peter ;
Dimitrakopoulou-Strauss, A. .
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2017, 44 (05) :776-787
[8]   Tumor target prostate specific membrane antigen (PSMA) and its regulation in prostate cancer [J].
Ghosh, A ;
Heston, WDW .
JOURNAL OF CELLULAR BIOCHEMISTRY, 2004, 91 (03) :528-539
[9]   [68Ga]Ga-P16-093 as a PSMA-Targeted PET Radiopharmaceutical for Detection of Cancer: Initial Evaluation and Comparison with [68Ga]Ga-PSMA-11 in Prostate Cancer Patients Presenting with Biochemical Recurrence [J].
Green, Mark A. ;
Hutchins, Gary D. ;
Bahler, Clinton D. ;
Tann, Mark ;
Mathias, Carla J. ;
Territo, Wendy ;
Sims, Justin ;
Polson, Heather ;
Alexoff, David ;
Eckelman, William C. ;
Kung, Hank F. ;
Fletcher, James W. .
MOLECULAR IMAGING AND BIOLOGY, 2020, 22 (03) :752-763
[10]   Prostate Cancer Theranostics: Concurrent Approvals by the Food and Drug Administration of the First Diagnostic Imaging Drug Indicated to Select Patients for a Paired Radioligand Therapeutic Drug [J].
Hofling, A. Alex ;
Fotenos, Anthony F. ;
Niu, Gang ;
Fallah, Jaleh ;
Agrawal, Sundeep ;
Wang, Sue-Jane ;
Marzella, Libero .
JOURNAL OF NUCLEAR MEDICINE, 2022, 63 (11) :1642-1643
1234